Clinical Trial

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

Name: Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer — clinical trial record (NCT06585007)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MEDCARE

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.

Trial Details

NCT Number	NCT06585007
Lead Sponsor	Universitaire Ziekenhuizen KU Leuven
Conditions	Castration-resistant Prostate Cancer, Oligoprogressive
Enrollment	246 participants
Start Date	2023-12-19
Primary Completion	2029-01-20 (estimated)
Study Completion	2029-01-20 (estimated)
Updated on ClinicalTrials.gov	2024-09-05